

Phase 1 Trial: Quotient Code QSC303303, Sponsor Code LMNL6511C1002

Submission date 22/04/2025	Recruitment status No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 02/05/2025	Overall study status Deferred	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 16/05/2025	Condition category Other	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

Plain English summary of protocol

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. Full details will be added to the study record within 30 months after the trial has ended.

Contact information

Type(s)

Public, Scientific

Contact name

Dr Clinical Trial Information

Contact details

Liminal BioSciences Limited, 3rd Floor, 1 Ashley Road

Altrincham

United Kingdom

WA14 2DT

-

info@liminalbiosciences.com

Type(s)

Principal investigator

Contact name

Dr Nand Singh

Contact details

Quotient Sciences Limited, Mere Way, Ruddington Fields

Nottingham

United Kingdom

NG11 6JS

+44 (0)330 303 1000
recruitment@weneedyou.co.uk

Additional identifiers

Integrated Research Application System (IRAS)
1011852

Protocol serial number
Quotient Code QSC303303, Sponsor Code LMNL6511C1002

Study information

Scientific Title
Phase 1 Trial: Quotient Code QSC303303, Sponsor Code LMNL6511C1002

Study objectives
The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. Full details will be added to the study record within 30 months after the trial has ended.

Ethics approval required
Ethics approval required

Ethics approval(s)
approved 14/05/2025, London - Surrey Borders Research Ethics Committee (Equinox House, City Link, Nottingham, NG2 4LA, United Kingdom; +44 (0)20 7104 8057; surreyboundaries.rec@hra.nhs.uk), ref: 25/LO/0200

Study design
Two part single centre randomized double-blind study to assess biomarkers safety tolerability and pharmacokinetics

Primary study design
Interventional

Study type(s)
Other

Health condition(s) or problem(s) studied
The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. Full details will be added to the study record within 30 months after the trial has ended.

Interventions
The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. Full details will be added to the study record within 30 months after the trial has ended.

Intervention Type

Drug

Phase

Phase I

Drug/device/biological/vaccine name(s)

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. Full details will be added to the study record within 30 months after the trial has ended.

Primary outcome(s)

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. Full details will be added to the study record within 30 months after the trial has ended.

Key secondary outcome(s)

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. Full details will be added to the study record within 30 months after the trial has ended.

Completion date

04/05/2026

Eligibility

Key inclusion criteria

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. Full details will be added to the study record within 30 months after the trial has ended.

Participant type(s)

Healthy volunteer

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Upper age limit

65 years

Sex

All

Key exclusion criteria

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. Full details will be added to the study record within 30 months after the trial has ended.

Date of first enrolment

02/06/2025

Date of final enrolment

04/05/2026

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

Quotient Sciences Limited

Mere Way, Ruddington Fields, Ruddington

Nottingham

United Kingdom

NG11 6JS

Sponsor information

Organisation

Liminal BioSciences Limited

Funder(s)

Funder type

Industry

Funder Name

Liminal BioSciences Limited

Results and Publications

Individual participant data (IPD) sharing plan

The datasets generated and/or analysed during the current study are not expected to be made available because of their high commercial sensitivity and the negligible benefit to the public of publication of results of non-therapeutic clinical trials.

IPD sharing plan summary

Not expected to be made available